NCT06988670

A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 35 (estimated)
• Sponsor: Extend Biosciences Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to investigate the safety, tolerability and efficacy of EXT608 in adults with hypoparathyroidism.

Conditions

• Hypoparathyroidism

Interventions

Type	Name	Description
DRUG	EXT608	Modified version of parathyroid hormone attached to vitamin D to extend half-life
OTHER	Placebo	Placebo for injection

Timeline

• Start date: 2025-05-05
• Primary completion: 2027-05-01
• Completion: 2027-05-01
• First posted: 2025-05-25
• Last updated: 2025-05-25

Locations

1 site across 1 country: Argentina

Regulatory

• FDA-regulated drug study